Clot Management Device Market Size, Share & Trends Analysis | United States | 2025-2031 | Includes: Neurovascular Detachable Coil, Neurovascular Catheter, Neurovascular Guidewire, and 3 more

The U.S. clot management device market was valued at nearly $2.8 billion in 2024. The market is projected to grow at a 3.0 percent CAGR to approach $3.4 billion by 2031.

This report covers neurovascular detachable coils, neurovascular catheters, neurovascular guidewires, neurovascular stents, liquid embolics, and peripheral vascular transcatheter embolization devices.

Quantitative coverage includes unit sales, average selling prices, market size, growth rates, procedure numbers, and company shares.

Qualitative coverage includes market drivers and limiters, mergers and acquisitions, portfolio updates, and competitive positioning across hospitals, comprehensive stroke centers, office based labs, and ambulatory settings that perform endovascular procedures.

Market Overview

Clot management in the United States reflects two large use cases. Neurovascular care focuses on aneurysm treatment and acute stroke intervention.

Peripheral vascular care focuses on embolization for oncology, trauma, and bleeding control and on treatment of vessel disease in aging and high risk populations.

Advances in imaging and access have expanded the number of treatable patients and have shifted more care toward endovascular approaches that reduce recovery time compared with open surgery.

In the brain, detachable coils and liquid embolic agents deliver precise aneurysm occlusion. Stents support vessel reconstruction and flow diversion when anatomy or pathology requires a durable scaffold.

In the peripheral system, physicians are using transcatheter embolization devices more widely for targeted therapy. Across settings, refinements in guidewires and catheters improve navigation, shorten procedure time, and reduce complexity for challenging anatomy.

Market Drivers

Improved imaging and earlier diagnosis. More frequent use of cerebral angiography, CT, and MRI has increased detection of unruptured aneurysms. Earlier detection has led to treatment of smaller aneurysms and to device portfolios that address a broader size range.

Shift toward endovascular treatment. Access devices have improved in flexibility, torque transmission, and distal support. Guidewires are easier to steer and microcatheters are smaller and more navigable, which makes it possible to treat lesions that were difficult to reach in the past. As access improves, endovascular options replace some surgical interventions.

New neurovascular technologies. Next generation detachable coils and liquid embolics improve occlusion durability and reduce recurrence. Neurovascular stents are adopting designs with optimized radial force and better conformability for complex anatomy. Intrasaccular stents are now available in the United States and are expanding clinical choices for select aneurysm types.

Expanding peripheral embolization. Transcatheter embolization devices benefit from better delivery systems and from new embolic materials. Use now spans oncology and is gaining roles in trauma and bleeding management.

Demographic factors. Peripheral stenting and related procedures rise with the aging population. Demand for hemodialysis access management is growing with diabetes prevalence and obesity. These patterns drive steady use of thrombus management devices and associated vascular access technologies.

Market Limiters

Limited specialist capacity. There are not enough trained neurointerventionalists to meet demand in all regions. Training pipelines take years to expand, which constrains procedure growth and slows equipment utilization in some centers.

Outcome uncertainty in specific techniques. Concerns persist about long term risks for some liquid embolic approaches when the nidus is not resected. While products like Onyx have shown higher cure rates in certain cases, complication rates and technique sensitivity still guide cautious adoption.

Price pressure in office based labs. Office based labs perform more peripheral vascular procedures and buy at lower prices than hospitals. Competition for OBL contracts is intense. Bundled offers that combine sheaths, guidewires, and catheters with core devices increase pressure on average selling prices and challenge narrow portfolios.

Portfolio cannibalization. Wider use of intrasaccular stents and advanced flow diversion can shift volumes away from detachable coils and clips in some aneurysm types. Product planning must address this mix effect.

Procurement and reimbursement constraints. Facilities respond to budget limits and payer policies by standardizing kits and vendors. This reduces device variety per case and can slow adoption of premium options without clear clinical and economic evidence.

Market Coverage and Data Scope

Quantitative coverage. Market size, market shares, market forecasts, growth rates, units sold, average selling prices, and procedure numbers.

Qualitative coverage. Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls where relevant, disruptive technologies, and disease overviews that influence therapy selection.

Time frame. Base year 2024, forecasts 2025 to 2031, historical data 2021 to 2023.

Data sources. Primary interviews with industry leaders, government physician and procedure data, regulatory data, hospital private data, import and export data, and the iData Research internal database.

Method note. Revenue is modeled from units multiplied by ASP and validated against imaging and procedure trends, installed base, and setting level adoption for neurovascular and peripheral endovascular programs.

Markets Covered and Segmentation

Detachable Coil Market

Device type. Bare platinum and coated coils.

Neurovascular Catheter Market

Device type. Over the wire microcatheter, flow directed microcatheter, guiding catheter.

Unit analysis by inner diameter. Less than 0.05 inch and greater than 0.05 inch.

Unit analysis by inner diameter. Less than 1 mm, between 1 and 2 mm, and greater than 2 mm.

Unit analysis by working length. Less than 100 cm, between 100 and 150 cm, and greater than 150 cm.

Neurovascular Guidewire Market

Coverage includes navigation and support profiles used with microcatheters and access systems.

Neurovascular Stent Market

Device type. Traditional stents, flow diversion stents, and intrasaccular stents.

Liquid Embolics Market

Device type. Neurovascular and peripheral vascular.

Transcatheter Embolization Market

Device type. Particle embolization, coil embolization, and plug embolization.

Competitive Analysis

Medtronic remains a leading player with strong share in liquid embolics and leadership in neurovascular stents. Flow diversion platforms continue to define treatment in appropriate aneurysm types.

Stryker ranks second on strength in detachable coils and neurovascular guidewires and has announced plans to expand its venous thromboembolism footprint through acquisition to complement its neurovascular business.

Terumo holds notable positions in guiding catheters and intrasaccular solutions, and participates in neurovascular stents with multiple device families.

Other manufacturers participate across coils, embolics, access devices, and peripheral embolization. Competitive advantage is shaped by portfolio breadth, delivery performance, pricing strategies for OBLs, and support programs for stroke and endovascular teams.

Technology and Practice Trends

Access and navigation. Hydrophilic coatings, refined distal support, and improved torque response reduce procedure time and enable safer navigation in small or tortuous vessels.

Flow diversion and intrasaccular devices. These stents target durable remodeling and occlusion. Wider indication coverage may shift mix away from some coil segments in selected cases.

Liquid embolic formulation. Advances focus on radiopacity, control, and handling to improve precision and confidence.

Peripheral embolization. Delivery systems are improving in pushability and stability, which supports use in oncology, trauma, and bleeding control.

Procedure standardization. Centers are building stroke and endovascular pathways that standardize trays, access tools, and inventory to reduce variation and cost.

Care Settings

The report covers hospitals, comprehensive stroke centers, community hospitals that perform elective aneurysm work, ambulatory sites with endovascular capability, and office based labs that perform peripheral vascular procedures.

Setting differences affect product choice, delivery system preferences, kit standardization, and achievable price corridors.

Geography

This edition covers the United States.

Why This Report

Where is the largest and fastest growing opportunity within the U.S. clot management device market and how do coils, stents, embolics, catheters, guidewires, and peripheral embolization each contribute to growth through 2031.

How does the clot management device market relate to imaging capacity and stroke system readiness, and how should planning account for rising detection of small aneurysms and for evolving acute stroke protocols.

What forces will shape the market going forward, including the shift from open surgery to endovascular treatment, supply strategies for office based labs, and the effect of bundled offerings on price and access.

How will new intrasaccular stents and advances in flow diversion affect product mix relative to detachable coils and to surgical clips for aneurysm management.

Which access trends matter most for case time and outcomes, including the role of hydrophilic coatings, distal support, and microcatheter inner diameter and working length.

How will demographic change and dialysis growth influence peripheral thrombus management and what are the implications for embolization demand and access technology.

What is the expected balance between hospital and OBL purchasing, and how will pricing, kit design, and service contracts adapt to each channel.

What risks could slow growth, including limited specialist capacity, reimbursement constraints, ASP pressure from bundled deals, and outcome concerns in select liquid embolic techniques.

How should commercial teams plan for portfolio cannibalization, where intrasaccular devices and flow diversion may shift units away from coils, and how can training and evidence programs maintain overall account value.

Where are the most practical levers for providers and suppliers, such as pathway standardization, inventory planning, and support for stroke readiness and peripheral embolization programs.

The U.S. clot management device market report from iData Research answers these questions with segment and setting models, company share analysis, procedure and pricing detail, and coverage that links technique choices to device demand.

Use it to size opportunities by category, plan product roadmaps, align service programs with provider constraints, and set targets for pricing, contracting, and inventory.